Sign in Subscribe

Topic

publication

A collection of 62 issues

Gemcitabine pathway published in Pharmacogenetics and Genomics

Gemcitabine is a cancer drug used to treat solid tumors as well as certain blood cancers. It can be administered alone or in combination with other drugs as part of a chemotherapy regimen. The genetic variants hypothesized to play a role in the variability of patient response to gemcitabine as

Tramadol pathway summary published in PG&G

Tramadol is a centrally acting opioid analgesic used to relieve moderate to severe pain. It is administered as a racemic mixture of (+) and (-) enantiomers and exerts its analgesic effect via activating the µ-opioid receptor and inhibiting the neurotransmitter reuptake. Tramadol metabolism to its major active metabolite O-desmethyl tramadol (M1)

SLC22A1 VIP Summary Published in PG&G

Solute carrier family 22 (organic cation transporter), member 1 (SLC22A1, also called OCT1) is an important drug transporter mediating the hepatic uptake of many commonly used drugs. Several SLC22A1 variants have functional consequences and have been associated with altered disposition and response for drugs such as metformin, imatinib, sorafenib, tropisetron,

Canadian pharmacogenomics group recommends genetic testing for patients prescribed carbamazepine

In a recent article published online in the journal Epilepsia, the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) has recommended genetic testing for the alleles HLA-B*15:02 and HLA-A*31:01 in all carbamazepine-naive patients before initiation of treatment. In patients who test positive for either of these alleles,

PG&G publication: Mycophenolic acid Pathway

Mycophenolic acid (MPA) is an immunosuppressive agent used to prevent rejection in organ transplantation. We recently have published this pathway summary in the Pharmacogenetics and Genomics Journal.The article and included figure describe the metabolism of MPA and its prodrug mycophenolate mofetil. MPA is a noncompetitive, selective and reversible inhibitor

Venlafaxine Pathway published in PG&G

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed for the treatment of depression disorders. We recently have published the Venlafaxine Pathway summary in the Pharmacogenetics and Genomics Journal.The article describes the metabolism of venlafaxine, with cytochrome P450 2D6 (CYP2D6) being the major enzyme involved in the formation of its

The Curation Economy

In an October 7th article in The Huffington Post blog section, Steve Rosenbaum discusses the development of a so-called "Curation Economy". Rosenbaum writes that the creation of content on the web is increasing at an exponential rate, leading to a massive amount of raw and unfiltered data. This

CPIC publishes guidelines for IFNL3 (IL28B) and peginterferon alpha based regimens

Guidelines regarding the use of IFNL3 (formerly known as IL28B) genotypes in peginterferon alpha based therapies have been accepted for publication in the Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Hepatitis C virus (HCV) infection affects more than 150 million people worldwide and is one of

Tamoxifen Pharmacokinetic Pathway Published

Tamoxifen, a selective estrogen receptor modulator, is used in the treatment and prevention of estrogen receptor positive breast cancer. The paper detailing the pharmacokinetic pathway of tamoxifen has been published by PG&G and can be found online. The pathway can also be found on our website. View all

CYP2C8 VIP published in PG&G

CYP2C8 is a member of the cytochrome P450 family of drug metabolizing enzymes. It plays a major role in the metabolism of many commonly used drugs. Several CYP2C8 SNPs have been associated with variability in metabolism, disposition and response for drugs such as repaglinide, rosiglitazone, pioglitazone, paclitaxel, bisphosphonates, amiodarone and